Kandy Therapeutics
Breakthrough treatment for chronic debilitating Women’s Health conditions
KaNDy Therapeutics is a UK based clinical-stage company focused on optimizing the potential of NT-814 as a breakthrough medicine for the treatment of chronic debilitating Women’s Health conditions.
NT-814 is a first-in-class, once daily, dual mechanism neurokinin-1,3 receptor antagonist. The medicine is being developed as a non-hormonal alternative to hormone replacement therapy for the treatment of postmenopausal symptoms (PMS).
NT-814 has been spun out of NeRRe Therapeutics Holdings Ltd into KaNDy Therapeutics Ltd, a separate legal entity. The new company will advance the development of NT-814 into Phase 2b in the lead indication PMS while also exploring its potential in other Women’s Health indications. All formulation, pre-clinical and clinical safety and efficacy data, and intellectual property associated with NT-814 have been transferred to the new company.
CEO Mary Kerr
Advent Contact Kaasim Mahmood
Exited Insvestment
Advent Life Sciences Announces Growth of Investment Team with Three Senior Appointments
Press Release. 26 May 2022, London, UK: Advent Life Sciences, a leading transatlantic venture and growth investor focused on building innovative life science companies in the UK, Europe, and…
Read More
Advent Life Sciences’ founded Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets
Press Release. This investment will fund Amphista Therapeutics’ growing pipeline of potent and selective bifunctional molecules, known as ‘Amphistas’ to the clinic and extend its proprietary platform. London, UK,…
Read More
